This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Renal Diseases  • Acute Renal Failure  • Rheumatology  • Osteoporosis  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2009;302(8):838.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Reports of renal problems in patients taking a once-yearly infusion of zoledronic acid for the treatment of osteoporosis, Paget disease, or for the prevention or treatment of glucocorticoid-induced osteoporosis have prompted new warnings from the US Food and Drug Administration (FDA) and the product's makers.

The FDA alerted physicians that it has received 24 reports of patients developing impaired renal function or acute renal failure after receiving an infusion of the drug, which is marketed as Reclast (http://www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyNewsletter/UCM168579.pdf). Of these patients, 18 required hospitalization and 7 died, according to the agency. More than half had medical conditions that put them at risk of kidney problems or were concurrently taking nephrotoxic medications. The drug's manufacturer has also updated the labeling of the drug to note such postmarketing reports.

The agency is advising physicians to avoid using this drug in patients with severe renal impairment, to make . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?